SCHEMBL20176002

SCHEMBL20176002

Cc1ccc(/C=C/c2cc(N)c3ncccc3c2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.49
MEN1 O00255 3/20 0.49
MAPT P10636 3/20 0.49
NPC1 O15118 1/20 0.49
CASP3 P42574 1/20 0.49
RAB9A P51151 1/20 0.49
ATM Q13315 1/20 0.49
SENP7 Q9BQF6 1/20 0.49
SENP6 Q9GZR1 1/20 0.49
CCR1 P32246 2/20 0.43
CCR8 P51685 2/20 0.43
COMT P21964 1/20 0.43
CCR5 P51681 1/20 0.43
PSMD14 O00487 1/20 0.43
COPS5 Q92905 1/20 0.43
SLC40A1 Q9NP59 2/20 0.42
NFKBIA P25963 1/20 0.42
RELA Q04206 1/20 0.42
FGF23 Q9GZV9 1/20 0.42
LMNA P02545 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20176001 0.82 COMT (0.59) KMT2AMEN1MAPTNPC1CASP3
SCHEMBL2478261 0.77 PSMD14 (0.62) MAPTCCR1CCR8COMTCCR5
SCHEMBL454942 0.70 CYP1A2 (0.55) KMT2AMEN1MAPTRAB9ASLC40A1
SCHEMBL7548538 0.70 KDM4E (0.52) MAPTNPC1RAB9AATMCCR1
SCHEMBL17081149 0.70 PTGS1 (0.52) MAPTRAB9ARELAALDH1A1KDM4E
Bromide SCHEMBL1143538 0.69 CYP1A2 (0.53) KMT2AMEN1MAPTRAB9ASLC40A1
SCHEMBL20176007 0.69 PDGFRB (0.56) KMT2AMEN1RAB9ARELAALDH1A1
SCHEMBL2471617 0.69 SLC40A1 (0.47) KMT2AMEN1MAPTNPC1RAB9A
8-Aminoquinoline SCHEMBL28223669 0.68 LMNA (0.53) KMT2AMEN1MAPTNPC1CASP3
SCHEMBL8439027 0.68 SLC40A1 (0.52) KMT2AMEN1MAPTRAB9ACCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180141911-A1 Quinoline Derivatives for Diagnosis and Treatment of Alzheimer's Disease NORTHEASTERN UNIVERSITY 2018-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141911-A1 Quinoline Derivatives for Diagnosis and Treatment of Alzheimer's Disease MAPT, PSEN1, PSEN2 KMT2A 2720/4885MEN1 1230/4885MAPT 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.